Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
99% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PGNX' s Cash to Debt Range Over the Past 10 Years
Min: 65  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.62
PGNX's Equity to Asset is ranked lower than
57% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PGNX: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
PGNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.89 Max: 0.98
Current: 0.62
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
98% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -0.77
M-Score: 52.64
WACC vs ROIC
20.91%
-322.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -205.30
PGNX's Operating margin (%) is ranked lower than
60% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. PGNX: -205.30 )
Ranked among companies with meaningful Operating margin (%) only.
PGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 12.17
Current: -205.3
-878.82
12.17
Net-margin (%) -203.56
PGNX's Net-margin (%) is ranked lower than
60% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. PGNX: -203.56 )
Ranked among companies with meaningful Net-margin (%) only.
PGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 12.24
Current: -203.56
-876.82
12.24
ROE (%) -39.89
PGNX's ROE (%) is ranked lower than
54% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. PGNX: -39.89 )
Ranked among companies with meaningful ROE (%) only.
PGNX' s ROE (%) Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: -39.89
-87.75
16.86
ROA (%) -27.28
PGNX's ROA (%) is ranked higher than
50% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. PGNX: -27.28 )
Ranked among companies with meaningful ROA (%) only.
PGNX' s ROA (%) Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: -27.28
-79.08
14.53
ROC (Joel Greenblatt) (%) -1338.21
PGNX's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. PGNX: -1338.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 208.07
Current: -1338.21
-1585.16
208.07
Revenue Growth (3Y)(%) -32.50
PGNX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. PGNX: -32.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -15.8 Max: 72.1
Current: -32.5
-55.5
72.1
EBITDA Growth (3Y)(%) -17.30
PGNX's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PGNX: -17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: -8.3 Max: 50.5
Current: -17.3
-46.4
50.5
EPS Growth (3Y)(%) -18.10
PGNX's EPS Growth (3Y)(%) is ranked lower than
66% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. PGNX: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.5  Med: -6.15 Max: 221.1
Current: -18.1
-73.5
221.1
» PGNX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PGNX Guru Trades in Q3 2015

Ken Fisher 83,250 sh (New)
Paul Tudor Jones 2,392,099 sh (+0.18%)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 2,978,950 sh (-7.54%)
» More
Q4 2015

PGNX Guru Trades in Q4 2015

Ken Fisher 140,191 sh (+68.40%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,370,760 sh (-0.89%)
Chuck Royce 2,282,250 sh (-23.39%)
» More
Q1 2016

PGNX Guru Trades in Q1 2016

Murray Stahl 67,200 sh (unchged)
Ken Fisher 140,191 sh (unchged)
Paul Tudor Jones 2,364,488 sh (-0.26%)
Chuck Royce 2,138,350 sh (-6.31%)
» More
Q2 2016

PGNX Guru Trades in Q2 2016

Mario Gabelli 25,000 sh (New)
Ken Fisher 140,361 sh (+0.12%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (-0.93%)
Chuck Royce 1,913,350 sh (-10.52%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:XBIT, NAS:ARNA, NAS:TGTX, NAS:TLGT, NAS:ADXS, NAS:ARWR, NAS:DVAX, NAS:PTCT, OTCPK:ZLDPF, NAS:SRNE, AMEX:BTX, NAS:XNPT, NAS:VSAR, NAS:RGNX, NAS:CLDX, NAS:MYOK, NAS:OMER, NAS:NSTG, NAS:SPPI, NAS:NDRM » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.

Ratios

vs
industry
vs
history
P/B 5.75
PGNX's P/B is ranked lower than
67% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. PGNX: 5.75 )
Ranked among companies with meaningful P/B only.
PGNX' s P/B Range Over the Past 10 Years
Min: 1.08  Med: 3.55 Max: 8.82
Current: 5.75
1.08
8.82
P/S 24.34
PGNX's P/S is ranked lower than
66% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. PGNX: 24.34 )
Ranked among companies with meaningful P/S only.
PGNX' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 9.8 Max: 177.27
Current: 24.34
1.88
177.27
Current Ratio 5.14
PGNX's Current Ratio is ranked higher than
54% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. PGNX: 5.14 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.53 Max: 32.92
Current: 5.14
2.67
32.92
Quick Ratio 5.14
PGNX's Quick Ratio is ranked higher than
55% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. PGNX: 5.14 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.53 Max: 32.92
Current: 5.14
2.67
32.92
Days Sales Outstanding 74.67
PGNX's Days Sales Outstanding is ranked lower than
58% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. PGNX: 74.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 32.86 Max: 180.24
Current: 74.67
0.36
180.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.50
PGNX's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. PGNX: -14.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.6  Med: -11.6 Max: -2.1
Current: -14.5
-73.6
-2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.55
PGNX's Price/Net Cash is ranked lower than
84% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. PGNX: 27.55 )
Ranked among companies with meaningful Price/Net Cash only.
PGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.35 Max: 27.55
Current: 27.55
1.59
27.55
Price/Net Current Asset Value 17.31
PGNX's Price/Net Current Asset Value is ranked lower than
82% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. PGNX: 17.31 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 5.75 Max: 18.68
Current: 17.31
1.48
18.68
Price/Tangible Book 14.09
PGNX's Price/Tangible Book is ranked lower than
83% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. PGNX: 14.09 )
Ranked among companies with meaningful Price/Tangible Book only.
PGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.22  Med: 5.07 Max: 14.09
Current: 14.09
1.22
14.09
Price/Median PS Value 2.48
PGNX's Price/Median PS Value is ranked lower than
84% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. PGNX: 2.48 )
Ranked among companies with meaningful Price/Median PS Value only.
PGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.26 Max: 13.3
Current: 2.48
0.23
13.3
Earnings Yield (Greenblatt) (%) -9.82
PGNX's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. PGNX: -9.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.18  Med: 1.8 Max: 10.2
Current: -9.82
-10.18
10.2

More Statistics

Revenue (TTM) (Mil) $17.42
EPS (TTM) $ -0.50
Beta2.57
Short Percentage of Float18.39%
52-Week Range $3.61 - 8.37
Shares Outstanding (Mil)69.99

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 73 68 138
EPS ($) 0.13 -0.37 0.76
EPS w/o NRI ($) 0.13 -0.37 0.76
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PGNX-US :... Sep 23 2016
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 14, 2016 Sep 14 2016
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... Sep 13 2016
Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial Sep 07 2016
Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial Sep 07 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 06 2016
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Sep 06 2016
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Sep 06 2016
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Sep 06 2016
Progenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry... Sep 02 2016
Progenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry... Sep 02 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 31 2016
PROGENICS PHARMACEUTICALS INC Financials Aug 13 2016
Valeant’s Relistor Said to Draw Interest of Potential Buyers Aug 05 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
Progenics reports 2Q loss Aug 04 2016
Progenics reports 2Q loss Aug 04 2016
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results Aug 04 2016
Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results Aug 04 2016
Biotech Week In Review: Valeant, Progenics, Relistor and Vesneo – Valeant Pharmaceuticals Intl Inc... Jul 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)